In platinum resistant/ refractory ovarian cancer PM01183 (lurbinectedin) produced an overall response rate of 27%, reported the results of a phase 2 trial presented in the proffered papers session for gynecological cancers at ESMO 2012 in Vienna. PM01183 is a new synthetic entity belonging to the tetrahydroisoquinoline family, which binds to the DNA minor groove inducing DNA breaks and transcription blockage. Read more
here.
No comments:
Post a Comment